Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Abiad Visits the Karantina Warehouse and Public Hospital with a Delegation from the Republic of Korea and UNICEF

 
Following the announcement of new contribution from the Republic of Korea to ensure new-borns’ lifesaving care across selected governmental hospitals and the availability of essential paediatric acute medications in primary healthcare centres, the minister of public health held a joint field visit to the Karantina warehouse and hospital with Korean Ambassador to Lebanon and UNICEF Representative. 

The new funding will ensure the access of vulnerable populations to essential medications at primary healthcare centres and intensive lifesaving care services in public hospitals to avoid any supply rupture and allow timely access to acute treatments for children and mothers.  

The Minister of Public Health, Dr. Firass Abiad, indicated that "this donation will contribute to supporting the most vulnerable". He pointed out that "this is not the first time that the Republic of Korea  and UNICEF have stood by Lebanon.  through cooperation with partners, the Ministry of Public Health, in light of the difficult economic and political circumstances in Lebanon and the fact that Lebanon is hosting large numbers of displaced people, is trying to fulfill its duties towards everyone by providing health services and medicine in Primary health care centers".

Ambassador of the Republic of Korea in Lebanon, Mr.  Il Park said: “Korea recognizes the importance of providing essential healthcare services to the most vulnerable members of society, particularly children and newborns. We firmly believe that every child deserves the right to receive proper medical attention and care, regardless of their circumstances.”

The procured acute medications includes antibiotics, and anti-inflammatories allow to fill the gap in the acute medication supply induced by high demand for care from the most vulnerable children in Lebanon. Supporting vulnerable families to cover the out of pocket payment for their infants and children intensive care services helps eliminate the financial barrier to accessing lifesaving care. 

Edouard Beigbeder, UNICEF Representative in Lebanon, emphasized the organization's dedication to bridging vital healthcare access disparities and maintaining life-saving assistance for mothers and children in Lebanon. “Thanks to the ongoing generous support from the Republic of Korea, we can broaden our initiatives to encompass more vulnerable areas and additional hospitals, with a particular focus on enhancing support in Baalbek and Akkar."
    ...
    9
ATC Name B/G Ingredients Dosage Form Price
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g 0.5g Injectable powder for solution 3,455,595 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g 0.5g Injectable powder for solution+diluent 433,869 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g, Lidocaine (ampoule) - 0.5g Injectable powder for solution+diluent 403,153 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g, Lidocaine (ampoule) - 0.5g Injectable powder for solution+diluent 403,153 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g 0.5g Injectable powder for solution 3,455,595 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g 0.5g Injectable powder for solution+diluent 511,940 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g 0.5g Injectable powder for solution+diluent 511,940 L.L
N01BB02 LIDOCAINE ARWAN G Lidocaine (HCl) - 0.5% 0.5% Injectable solution 1,995,158 L.L
S01BA14 LOTEMAX B Loteprednol etabonate - 0.5% 0.5% Drops suspension 1,038,790 L.L
C01AA05 LANOXIN B Digoxin - 0.25mg 0.25mg Tablet 215,015 L.L
S01EE03 LUMIGAN B Bimatoprost - 0.1mg/ml 0.1mg/ml Drops solution 740,457 L.L
S01EE03 LUMIGAN B Bimatoprost - 0.1mg/ml 0.1mg/ml Drops solution 740,457 L.L
D07AB02 LOCOID B Hydrocortisone butyrate - 1mg/g 0.1% Cream 215,015 L.L
D07AB02 LOCOID B Hydrocortisone butyrate - 1mg/g 0.1% Cream 215,015 L.L
D07AB02 LOCOID B Hydrocortisone butyrate - 0.1% 0.1% Lipocream 221,734 L.L
D07AB02 LOCOID B Hydrocortisone butyrate - 0.1% 0.1% Lipocream 221,734 L.L
D07AB02 LOCOID CRELO 0.1% B Hydrocortisone butyrate - 1mg/g 0.1% Emulsion 177,387 L.L
D07AB02 LOCOID CRELO 0.1% B Hydrocortisone butyrate - 1mg/g 0.1% Emulsion 177,387 L.L
D07AB02 LOCOID B Hydrocortisone butyrate - 0.1% 0.1% Lotion 201,576 L.L
D07AB02 LOCOID B Hydrocortisone butyrate - 0.1% 0.1% Lotion 201,576 L.L
C01AA05 LANOXIN PG B Digoxin - 0.05mg/ml 0.05mg/ml Elixir 307,740 L.L
S01GX02 LEVOPHTA B Levocabastine HCl - 0.5mg/ml 0.05% Suspension 682,672 L.L
J05AR01 LAMIVUDINE/ ZIDOVUDINE ARROW G Lamivudine - 150mg, Zidovudine - 300mg Tablet, coated, scored 15,643,319 L.L
S01XA20 LUBRI-TEARS G Carmellose sodium - 2mg Drops solution 792,867 L.L
D07XC01 LOTRIDERM B Betamethasone (dipropionate) - 0.5mg/g, Clotrimazole - 10mg/g Cream 470,345 L.L
G04BE30 LIF-DOL B Yohimbin HCl - 3.3mg, Thiamine - 5.5mg, Cyanocobalamine - 0.015mg, Ferrous fumarate - 50mg, Sildenafil citrate - 10mg Tablet, coated 231,653 L.L
J07CA LANTIGEN B B Streptococcus pneumoniae type 3 (antigenic extracts) - 63.2A.U./ml, Streptococcus pyogenes group A (antigenic extracts) - 126.2A.U./ml, Branhamella catarrhalis (antigenic extracts) - 39.9A.U./ml, Staphylococcus aureus (antigenic extracts) - 79.6A.U./ml, Haemophilus influenzae type b (antigenic extracts) - 50.2A.U./ml, Klebsiella pneumoniae (antigenic extracts) - 39.8A.U./ml Drops suspension 916,501 L.L
C09DA01 LOSANET-H G Losartan potassium - 50mg, Hydrochlorothiazide - 12.5mg Tablet 395,474 L.L
C09DA01 LOSARTAN/HYDROCHLOROTHIAZIDE ARROW LAB G Losartan potassium - 50mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 470,345 L.L
C09DA01 LOSARTAN/HYDROCHLOROTHIAZIDE BGR G Losartan potassium - 50mg, Hydrochlorothiazide - 12.5mg Tablet, coated 439,436 L.L
    ...
    9
Sitemap
© Copyrights reserved to Ministry of Public Health 2025